High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial.

Canioni, Danielle;Salles, Gilles;Mounier, Nicolas;Brousse, Nicole;Xerri, Luc;et.al.
(2008) Journal of clinical oncology : official journal of the American Society of Clinical Oncology — Vol. 26, n° 3, p. 440-446 (2008)

Files

CanioniDetalJClinOncol2008.pdf
  • Restricted Access
  • Adobe PDF
  • 374.23 KB
Request a copy

Details

Authors
  • Canioni, Danielle
    Author
  • Salles, Gilles
    Author
  • Mounier, NicolasUCLouvain
    Author
  • Brousse, NicoleUCLouvain
    Author
  • Sonet, AnneUCLouvain
    Author
  • Xerri, Luc
    Author
Show more
Abstract
High amounts of intratumoral macrophages have been shown to correlate with poor prognosis in patients with follicular lymphoma (FL) treated with chemotherapy without rituximab. We tried to establish whether intratumoral macrophage count (MC) definitely is able to predict the outcome of FL patients in the rituximab era.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Canioni, D., Salles, G., Mounier, N., Brousse, N., Keuppens, M., Morchhauser, F., Lamy, T., Sonet, A., Rousselet, M.-C., Foussard, C., & Xerri, L. (2008). High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26(3), 440-446. https://doi.org/10.1200/JCO.2007.12.8298 (Original work published 2008)